Neuroscience
FierceBiotech reported today about a failed Phase III trial of Acadia's Pimavanserin in a study of Parkinson's Disease Psychosis (sometimes abbreviated as "PDP"):
ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
Pimavanserin Misses Primary Endpoint of Antipsychotic Efficacy; Meets Key Secondary Endpoint of Motoric Tolerability
[snip]
SAN DIEGO -- Sep. 1, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis, or PDP. The study did not meet its primary endpoint of antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS. Pimavanserin met the key secondary endpoint of motoric tolerability as measured using the Unified Parkinson's Disease Rating Scale, or UPDRS. Pimavanserin was safe and well tolerated, with the frequency of adverse events generally similar in the pimavanserin and placebo arms.
[snip]
Read the full article
NOTE: Pimavanserin is a 5-HT2A receptor inverse agonist.
- Alzheimer Disease: Targacept's Failed Tc-1734 Phase 2b Trial
From a Targacept press release:Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over Donepezil July 14, 2014 "Winston-Salem, NC – Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company...
- Neuropsychology Abstract Of The Day: Scales To Measure Psychosis In Parkinson's Disease
Goetz CG. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism and Related Disorders. 2009 Dec; 15 Suppl 3, 38-341 Hallucinations and psychotic behaviors are a frequent non-motor aspect of Parkinson's disease and its treatment. These...
- Alzheimer Disease: Dimebon Results
A press release from earlier today by Pfizer: Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program [snip] "About the CONNECTION Study "CONNECTION is a Phase 3, multi-national,...
- Parkinson's: Wii-hab And Symptom Improvement
From The Times (UK): The latest Parkinson’s treatment: Wii-hab Parkinson’s disease symptoms could be controlled by a game that can be bought on every high street, says a recent study Simon Crompton 21 September 2009 [snip] This summer, the Medical...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
Neuroscience
Acadia's Pimavanserin and Parkinson Disease Psychosis
FierceBiotech reported today about a failed Phase III trial of Acadia's Pimavanserin in a study of Parkinson's Disease Psychosis (sometimes abbreviated as "PDP"):
ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
Pimavanserin Misses Primary Endpoint of Antipsychotic Efficacy; Meets Key Secondary Endpoint of Motoric Tolerability
[snip]
SAN DIEGO -- Sep. 1, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis, or PDP. The study did not meet its primary endpoint of antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS. Pimavanserin met the key secondary endpoint of motoric tolerability as measured using the Unified Parkinson's Disease Rating Scale, or UPDRS. Pimavanserin was safe and well tolerated, with the frequency of adverse events generally similar in the pimavanserin and placebo arms.
[snip]
Read the full article
NOTE: Pimavanserin is a 5-HT2A receptor inverse agonist.
- Alzheimer Disease: Targacept's Failed Tc-1734 Phase 2b Trial
From a Targacept press release:Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over Donepezil July 14, 2014 "Winston-Salem, NC – Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company...
- Neuropsychology Abstract Of The Day: Scales To Measure Psychosis In Parkinson's Disease
Goetz CG. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism and Related Disorders. 2009 Dec; 15 Suppl 3, 38-341 Hallucinations and psychotic behaviors are a frequent non-motor aspect of Parkinson's disease and its treatment. These...
- Alzheimer Disease: Dimebon Results
A press release from earlier today by Pfizer: Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program [snip] "About the CONNECTION Study "CONNECTION is a Phase 3, multi-national,...
- Parkinson's: Wii-hab And Symptom Improvement
From The Times (UK): The latest Parkinson’s treatment: Wii-hab Parkinson’s disease symptoms could be controlled by a game that can be bought on every high street, says a recent study Simon Crompton 21 September 2009 [snip] This summer, the Medical...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...